Rhythm Pharmaceuticals Secures $25,000,000 Series B Financing Round

  • Feed Type
  • Date
    6/4/2012
  • Company Name
    Rhythm Pharmaceuticals
  • Mailing Address
    855 Boylston Street, 11th Floor Boston, MA 02116
  • Company Description
    Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases.
  • Website
    http://www.rhythmtx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Rhythm will use the proceeds to continue advancing its small-peptide therapeutics for metabolic diseases through Phase 2 clinical trials. RM-131 is a ghrelin agonist currently in a Phase 2 clinical trial for the treatment of diabetic gastroparesis. RM-493, an agonist of the melanocortin 4 receptor (MC4R), is currently in Phase 1 clinical trials for the treatment of obesity and diabetes.
  • M&A Terms
  • Venture Investor
    MPM Capital
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.